JP7437490B2 - ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 - Google Patents

ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 Download PDF

Info

Publication number
JP7437490B2
JP7437490B2 JP2022509595A JP2022509595A JP7437490B2 JP 7437490 B2 JP7437490 B2 JP 7437490B2 JP 2022509595 A JP2022509595 A JP 2022509595A JP 2022509595 A JP2022509595 A JP 2022509595A JP 7437490 B2 JP7437490 B2 JP 7437490B2
Authority
JP
Japan
Prior art keywords
compound
substituted
certain embodiments
unsubstituted
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022509595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542184A (ja
Inventor
バーサヴィッヒ,マシュー,ジー.
キュイ,ダン
ダウリング,ジェームズ,イー.
ハーン,クリストファー,エヌ.
ハリソン,ブライス,エー.
リン,フー-ヤン
リッパ,ブレイズ,エス.
ロジャーズ,ブルース,エヌ.
トロースト,ドーン,エム.
ゾン,チェン
コンズ,カイル,ディー.
ジェラシュート,アレクシー,アイ.
キム,ビュンチャン
ラフィ,サルマ
デイ,テイラー
ヒッキー,ユージーン
ハウアン,エヴェリン
ザラー,ロバート
Original Assignee
モーフィック セラピューティック,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モーフィック セラピューティック,インコーポレイテッド filed Critical モーフィック セラピューティック,インコーポレイテッド
Publication of JP2022542184A publication Critical patent/JP2022542184A/ja
Priority to JP2024018765A priority Critical patent/JP7717202B2/ja
Application granted granted Critical
Publication of JP7437490B2 publication Critical patent/JP7437490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
JP2022509595A 2019-10-16 2020-10-16 ヒトインテグリン(アルファ-4)(ベータ-7)の阻害 Active JP7437490B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018765A JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン(アルファ-4)(ベータ-7)の阻害

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
US62/916,062 2019-10-16
PCT/US2020/056001 WO2021076902A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α 4 β 7

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018765A Division JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン(アルファ-4)(ベータ-7)の阻害

Publications (2)

Publication Number Publication Date
JP2022542184A JP2022542184A (ja) 2022-09-29
JP7437490B2 true JP7437490B2 (ja) 2024-02-22

Family

ID=73198501

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2022509595A Active JP7437490B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリン(アルファ-4)(ベータ-7)の阻害
JP2022523102A Active JP7437495B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリンα4β7の阻害
JP2021576053A Active JP7209116B2 (ja) 2019-10-16 2021-10-15 ヒトインテグリンα4β7の阻害
JP2023000761A Active JP7500785B2 (ja) 2019-10-16 2023-01-06 ヒトインテグリンα4β7の阻害
JP2024018866A Active JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα4β7の阻害
JP2024018765A Active JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン(アルファ-4)(ベータ-7)の阻害
JP2024091304A Active JP7869261B2 (ja) 2019-10-16 2024-06-05 ヒトインテグリンα4β7の阻害

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2022523102A Active JP7437495B2 (ja) 2019-10-16 2020-10-16 ヒトインテグリンα4β7の阻害
JP2021576053A Active JP7209116B2 (ja) 2019-10-16 2021-10-15 ヒトインテグリンα4β7の阻害
JP2023000761A Active JP7500785B2 (ja) 2019-10-16 2023-01-06 ヒトインテグリンα4β7の阻害
JP2024018866A Active JP7702004B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリンα4β7の阻害
JP2024018765A Active JP7717202B2 (ja) 2019-10-16 2024-02-09 ヒトインテグリン(アルファ-4)(ベータ-7)の阻害
JP2024091304A Active JP7869261B2 (ja) 2019-10-16 2024-06-05 ヒトインテグリンα4β7の阻害

Country Status (37)

Country Link
US (3) US20240174632A1 (cg-RX-API-DMAC7.html)
EP (3) EP4045039B1 (cg-RX-API-DMAC7.html)
JP (7) JP7437490B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220102669A (cg-RX-API-DMAC7.html)
CN (4) CN119192137A (cg-RX-API-DMAC7.html)
AR (1) AR120244A1 (cg-RX-API-DMAC7.html)
AU (3) AU2020366435B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007284A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154269A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000959A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005759A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220205A (cg-RX-API-DMAC7.html)
CU (1) CU20220027A7 (cg-RX-API-DMAC7.html)
DK (1) DK4045039T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2022000081A (cg-RX-API-DMAC7.html)
EC (1) ECSP22038978A (cg-RX-API-DMAC7.html)
ES (1) ES3035561T3 (cg-RX-API-DMAC7.html)
FI (1) FI4045039T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250749T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071814T2 (cg-RX-API-DMAC7.html)
IL (2) IL319053A (cg-RX-API-DMAC7.html)
LT (1) LT4045039T (cg-RX-API-DMAC7.html)
MA (1) MA57399B1 (cg-RX-API-DMAC7.html)
MD (1) MD4045039T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004406A (cg-RX-API-DMAC7.html)
PE (1) PE20221829A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550886A1 (cg-RX-API-DMAC7.html)
PL (1) PL4045039T3 (cg-RX-API-DMAC7.html)
PT (1) PT4045039T (cg-RX-API-DMAC7.html)
PY (1) PY2065718A (cg-RX-API-DMAC7.html)
RS (1) RS66976B1 (cg-RX-API-DMAC7.html)
SI (1) SI4045039T1 (cg-RX-API-DMAC7.html)
TW (7) TWI775182B (cg-RX-API-DMAC7.html)
UA (1) UA130059C2 (cg-RX-API-DMAC7.html)
UY (1) UY38926A (cg-RX-API-DMAC7.html)
WO (3) WO2021076890A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202203872B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
BR112022007284A2 (pt) * 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
US20250195485A1 (en) * 2021-12-27 2025-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and medical use thereof
EP4585587A1 (en) 2022-09-09 2025-07-16 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and use thereof in medicine
CN120500479A (zh) 2022-12-22 2025-08-15 新特拉有限公司 α4β7整联蛋白拮抗剂及其用途
CN120957974A (zh) * 2023-02-21 2025-11-14 希四克斯探索有限公司 大环α4β7整合素抑制剂
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
CN119504796B (zh) * 2024-11-20 2026-03-10 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用
WO2026138844A1 (zh) * 2024-12-24 2026-07-02 湖北生物医药产业技术研究院有限公司 酰胺类化合物及其作为整合素α4β7拮抗剂的用途
WO2026156089A1 (en) 2025-01-17 2026-07-23 Eli Lilly And Company Small molecule alpha4beta7 integrin inhibitor for use in the treatment of inflammatory bowel disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531234A (ja) 2018-04-12 2021-11-18 モーフィック セラピューティック,インコーポレイテッド ヒトインテグリンα4β7のアンタゴニスト
JP2023500437A (ja) 2019-10-16 2023-01-06 モーフィック セラピューティック,インコーポレイテッド ヒトインテグリンα4β7の阻害

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425431T2 (de) 1993-03-31 2001-02-08 G.D. Searle & Co., Chicago 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998016524A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. HETEROCYCLIC DERIVATIVES AS FACTOR Xa INHIBITORS
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
ES2221227T3 (es) 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
SK288186B6 (sk) * 1999-05-07 2014-05-06 Encysive Pharmaceuticals, Inc. Deriváty kyseliny propiónovej, ktoré inhibujú väzbu integrínov na ich receptory, farmaceutické kompozície s ich obsahom a ich použitie
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
EP1214292B1 (en) 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
BR0113671A (pt) * 2000-08-30 2004-01-06 Pharmacia Corp Antagonistas de integrina alfa v beta 3 gem-substituìda
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック, インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
EP4159727B1 (en) * 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
ES2987796T3 (es) * 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531234A (ja) 2018-04-12 2021-11-18 モーフィック セラピューティック,インコーポレイテッド ヒトインテグリンα4β7のアンタゴニスト
JP2023500437A (ja) 2019-10-16 2023-01-06 モーフィック セラピューティック,インコーポレイテッド ヒトインテグリンα4β7の阻害

Also Published As

Publication number Publication date
AU2021361031A1 (en) 2023-06-08
JP2024054296A (ja) 2024-04-16
AU2026206251A1 (en) 2026-08-06
JP7209116B2 (ja) 2023-01-19
ZA202203872B (en) 2024-01-31
CR20220205A (es) 2022-07-22
SI4045039T1 (sl) 2025-07-31
US11104661B1 (en) 2021-08-31
JP2023036958A (ja) 2023-03-14
TWI775182B (zh) 2022-08-21
ES3035561T3 (en) 2025-09-04
RS66976B1 (sr) 2025-07-31
MD4045039T2 (ro) 2025-11-30
EP4045039B1 (en) 2025-04-23
JP2024054293A (ja) 2024-04-16
EP4228634A1 (en) 2023-08-23
TWI791304B (zh) 2023-02-01
TW202126624A (zh) 2021-07-16
IL319053A (en) 2025-04-01
CN119192137A (zh) 2024-12-27
CU20220027A7 (es) 2022-12-12
WO2021076902A1 (en) 2021-04-22
UY38926A (es) 2021-05-31
TW202500559A (zh) 2025-01-01
AU2020366435A1 (en) 2022-04-21
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
LT4045039T (lt) 2025-08-11
EP4559525A3 (en) 2025-08-20
WO2021076890A1 (en) 2021-04-22
DOP2025000034A (es) 2025-04-08
ECSP22038978A (es) 2022-06-30
PY2065718A (es) 2023-01-17
CO2022005759A2 (es) 2022-05-20
TW202315868A (zh) 2023-04-16
CN116783161A (zh) 2023-09-19
EP4045039A4 (en) 2023-12-13
TW202500558A (zh) 2025-01-01
FI4045039T3 (fi) 2025-06-20
JP7437495B2 (ja) 2024-02-22
IL292296A (en) 2022-06-01
JP2024116230A (ja) 2024-08-27
CL2022000959A1 (es) 2023-04-28
IL292296B2 (en) 2025-07-01
TWI900200B (zh) 2025-10-01
PL4045039T3 (pl) 2025-09-15
JP7702004B2 (ja) 2025-07-02
CA3154269A1 (en) 2021-04-22
KR20220102669A (ko) 2022-07-20
PH12022550886A1 (en) 2023-05-03
TW202244040A (zh) 2022-11-16
TWI888065B (zh) 2025-06-21
TW202332675A (zh) 2023-08-16
DOP2022000081A (es) 2022-07-31
UA130059C2 (uk) 2025-10-29
JP7717202B2 (ja) 2025-08-01
HUE071814T2 (hu) 2025-09-28
KR20230088376A (ko) 2023-06-19
CN115087444A (zh) 2022-09-20
AU2020366435B2 (en) 2026-05-28
TWI840047B (zh) 2024-04-21
WO2022081983A1 (en) 2022-04-21
CN115087444B (zh) 2024-09-17
JP7869261B2 (ja) 2026-06-02
US11370773B1 (en) 2022-06-28
CN116783161B (zh) 2026-04-03
IL292296B1 (en) 2025-03-01
JP2022542184A (ja) 2022-09-29
DK4045039T3 (da) 2025-06-30
TWI802477B (zh) 2023-05-11
WO2021076890A4 (en) 2021-06-10
MA57399B1 (fr) 2025-06-30
PE20221829A1 (es) 2022-11-29
JP2023500437A (ja) 2023-01-06
US20240174632A1 (en) 2024-05-30
ZA202303992B (en) 2024-06-26
CN122251398A (zh) 2026-06-23
HRP20250749T1 (hr) 2025-08-15
JP7500785B2 (ja) 2024-06-17
JP2022548809A (ja) 2022-11-22
BR112022007284A2 (pt) 2022-07-05
AR120244A1 (es) 2022-02-09
MX2022004406A (es) 2022-08-25
EP4045039A1 (en) 2022-08-24
EP4228634A4 (en) 2024-12-18
PT4045039T (pt) 2025-07-02
EP4559525B1 (en) 2026-08-05
EP4559525A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
JP7717202B2 (ja) ヒトインテグリン(アルファ-4)(ベータ-7)の阻害
CN114641473A (zh) Brd9双官能团降解剂及其使用方法
CN112312910A (zh) 人整合素α4β7拮抗剂
KR20020069362A (ko) 함질소환 화합물 및 이들을 포함하는 의약 조성물
TW202304875A (zh) 做為Kv1.3鉀SHAKER通道阻斷劑之芳基雜環化合物
JP7051009B2 (ja) アミノペプチダーゼa阻害剤及びそれを含む医薬組成物
EA052724B1 (ru) ИНГИБИРОВАНИЕ ИНТЕГРИНА ЧЕЛОВЕКА α4β7
OA21139A (en) Inhibiting human integrin ALPHA4BETA7.
CN100526301C (zh) 1,2-二(环式基)取代苯化合物
KR20020095418A (ko) Vla-4 억제제 화합물
KR20070015639A (ko) 함질소환 화합물 및 이들을 포함하는 의약 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220303

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220303

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220303

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220413

A25B Request for examination refused [due to the absence of examination request for another application deemed to be identical]

Free format text: JAPANESE INTERMEDIATE CODE: A2522

Effective date: 20220913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02